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T
he discovery in 1988 of endothelin-1 (ET-1) by Yanagisawa and colleagues in Japan
represented a landmark in the field of cardiovascular research.1 A combination of molecular
and pharmacological approaches revealed ET-1 as the most powerful vasoconstrictor yet
identified in biological systems. Since its discovery, a great deal of effort has been made towards
gaining a better understanding of the key roles—developmental, physiological, and pathologi-
cal—played by this peptide, particularly with regard to the cardiovascular system. In this review,
we will describe current knowledge on the endothelin system and focus on the cardiovascular
effects of ET-1 and its antagonism. We will review the evidence for the two therapeutic areas
mainly investigated, pulmonary arterial hypertension and heart failure, as well as outline its
important role in hypertension, renal dysfunction, and atherosclerosis.
MOLECULAR BIOLOGY OF ENDOTHELIN-1c
Endothelin synthesis and clearance
The endothelin family consists of three closely related peptides, ET-1, ET-2, and ET-3, each 21
amino acids in length and derived from separate genes. ET-1[1–21] is the main isoform produced in
the cardiovascular system and about which most is known; ET-2 is mainly produced within the
kidney and intestine, whereas ET-3 is predominantly found within the central nervous system
(tables 1 and 2). However, the roles of ET-2 and ET-3, except in embryonic development, remain
unclear.
ET-1 is not stored and released but instead generated in response to a range of stimuli, which
vary between different tissues (fig 1).2 It is generated mainly in endothelial cells of blood vessels
and requires several processing steps before the mature peptide is formed (fig 1). The final step in
the ET-1 pathway involves cleavage of the 38 amino acid ‘‘big ET-1’’ by the highly selective
membrane bound metalloproteinase, endothelin converting enzyme (ECE-1). ECE independent
pathways of ET-1 formation have also been described: they involve tissue chymases cleaving big
ET-1 to produce alternative intermediary peptides, such as ET-1[1–31], which has recently been
shown to cause vasoconstriction in the human skin microcirculation.w1
ET-1 is predominantly secreted abluminally and, as such, exerts paracrine actions. Therefore,
interpretation of ET-1 and big ET-1 plasma concentrations require some caution. Indeed, effects
on ET clearance rather than production are a major determinant of plasma concentration.
Nevertheless, they may be useful as an index of ET-1 synthetic activity.
Although its biological effects may last considerably longer, the plasma half life of ET-1 is , 2
minutes, owing to its efficient extraction in the pulmonary and renal vascular beds. This
extraction involves binding to cell surface clearance ETB receptors, followed by internalisation and
degradation, probably within lysosomes. Endothelins are also degraded by neutral endopepti-
dases (NEP), which are mainly found in the brush border vesicles of the proximal tubules of the
kidney.
Endothelin receptors
ET-1 exerts its actions through binding to specific receptors, the so called type A (ETA) and type B
(ETB) receptors. Both of them are G protein coupled transmembrane proteins, with different
molecular and pharmacological characteristics and functions based on their location. ET-1
binding to these receptors results in activation of the phosphatidyl inositol phospholipase C
pathway and initiates an array of intracellular events, with both short and long term effects, such
as rapid increase in intracellular calcium levels, activation of protein kinase C, and nuclear
signalling mechanisms.
The ETA receptor is predominantly expressed in the vascular smooth muscle cells and cardiac
myocytes. Its interaction with ET-1 results in vasoconstriction and cell proliferation. In contrast,
the ETB receptor is predominantly expressed on vascular endothelial cells and is linked to an
inhibitory G protein. Its activation results in nitric oxide (NO) induced vasodilatation and
prostacyclin release. This receptor is also present, at a much lower level, on the vascular smooth
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muscle cells, where its activation can contribute to vasocon-
striction. In addition, ETB receptors play a determinant role in
the clearance of circulating ET-1, particularly in the
pulmonary and renal vascular beds. In the absence of
disease, ET-1 actions result in a complex modulation of
vasomotor tone, tissue differentiation, and cell proliferation,
driven by the interplay between effects on ETA and ETB
receptors. However, experimental evidence suggests that, in
pathological states, ET receptors are differently regulated,
thus contributing to unbalanced effects tending towards
vasoconstriction and cell proliferation.
The more detailed basic science and molecular biology of
the endothelins have been reviewed elsewhere.2–4 w2
PHYSIOLOGICAL ACTIONS OF ENDOTHELIN-1
Understanding the role of ET-1 in human physiology has
followed directly from the development of a series of
endothelin agonists and, most importantly, antagonists.
Endothelin agonism
As yet, a selective ETA receptor agonist has not been
discovered. With regard to ETB receptors, sarafotoxin-6c
and ET-3 have been used as agonists, given their relative
selectivity for the ETB over the ETA receptors. In man, ET-1
produces a slow onset dose dependent vasoconstriction that
is sustained for up to two hours.w3 This response is largely
abolished by co-infusion of an ETA receptor antagonist,
suggesting that ET-1 vasoconstriction in resistance vessels is
predominantly ETA mediated.
5 This effect is preceded by a
transient vasodilatation that seems to be mediated by
endothelial ETB receptors.
Systemic intravenous infusion of ET-1 and big ET-1 causes
a dose dependent pressor effect, as well as a reduction in
heart rate.w4 These systemic effects are associated with falls
in coronary blood flow and coronary sinus oxygen saturation,
indicating the potential role of ET-1 in the regulation of
coronary vascular tone.
Endothelin antagonism
Various preclinical and clinical data support a pathogenic role
for ET-1 in a number of disease states. This has fuelled
research into the development of endothelin antagonists, in
search of the potential benefit that might derive from their
use in clinical practice. They are classified into two major
subgroups: ECE inhibitors and endothelin receptor antago-
nists.
ECE inhibition
Inhibition of ECE blocks the conversion of big ET-1 to ET-1
and is associated with vasodilatation and hypotension.5 Most
ECE inhibitors currently under development also inhibit
neutral endopeptidase (NEP), so that they have the combined
effect of inhibiting ET-1 production and potentiating
endogenous vasodilator mediators metabolised by NEP, such
as atrial natriuretic peptide and bradykinin (table 3). This
inhibition might also be extended to include triple inhibition
of ECE, NEP, and angiotensin converting enzyme (ACE),
with a potentially beneficial action in pathological conditions
such as heart failure and renal dysfunction.6 w5 In addition,
by blocking ET-1 generation, ECE inhibitors would act as
mixed ETA/ETB antagonists and, perhaps importantly, would
leave ET-1 clearance unaffected. However, so far, less
progress has been made clinically with the development of
drugs based on ECE inhibition than endothelin receptor
antagonism.
Endothelin receptor antagonism
Endothelin receptor antagonists are classified as ETA or ETB
selective, depending on their relative affinity for a receptor
subtype, or mixed ETA/ETB antagonists when relatively non-
selective (table 4). The two most used pharmacological
‘‘probes’’ to investigate the effects of endothelin receptor
antagonism, either locally and systemically, are two peptides
named BQ123 (antagonist of the ETA receptor) and BQ788
(antagonist of the ETB receptor). With regard to mixed ETA/
ETB receptor antagonists, a number of compounds have been
used for experimental studies but bosentan (Tracleer), an
orally available non-peptide antagonist, was the first of its
class to obtain approval for clinical use from the US Food and
Drug Administration and Europe’s European Medicines
Agency (EMEA), and is currently licensed for the treatment
of pulmonary arterial hypertension. It should be noted,
however, that the distinction between selective and mixed
(ETA/ETB) antagonists is not pharmacologically well defined.
The mixed antagonists still usually demonstrate a greater
affinity for the ETA receptor, whereas the ETA selective
antagonists, when used at relatively high doses, may act on
both receptors.w6
ETA receptor antagonism is associated with vasodilatation
in healthy volunteers.5 When administered systemically, the
Table 1 Sites of production of ET-1, ET-2, and ET-3
ET-1 ET-2 ET-3
c Endothelial cells c Kidney epithelial cells c Neurons
c Vascular smooth muscle cells c Gastrointestinal stromal cells c Glia
c Epithelial cells c Adrenal cells
c Hepatocytes c Lung epithelial cells
c Neurons c Gastrointestinal stromal cells
c Astrocytes c Kidney epithelial cells
Table 2 Classification of endothelin receptors
ETA ETB
c Agonist potency ET-1.ET-2..ET-3 ET-1 = ET-2 = ET-3
c Selective agonist None Endothelin-3,
sarafotoxin-6c,
BQ3020, IRL1620
c Main actions Vasoconstriction Vasodilatation
Mitogenesis Vasoconstriction
Angiogenesis Natriuresis
Matrix formation ET clearance
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ETA receptor antagonist BQ123 produces a dose dependent
reduction in blood pressure and systemic vascular resistance.w7
This indicates that ET-1 contributes to the maintenance of
vascular tone and blood pressure through its actions on the ETA
receptor. In contrast, administration of the ETB receptor
antagonist BQ788 produces amild vasoconstriction and pressor
effect.7 8 This suggests that endothelial vasodilatory ETB
receptors, known to be coupled to nitric oxide synthase, have
a physiological role in counterbalancing ETA mediated vascular
tone. Indeed, compared to isolated ETA receptor antagonism,
mixed ETA/ETB receptor antagonism produces less vasodilata-
tion and smaller falls in blood pressure.9 ETB receptor
antagonists have also been shown to increase plasma ET-1
concentrations in rodents and in man, presumably by
decreasing ET-1 clearance.8 w8
In addition to its vascular effects at ETA and ETB receptors,
ET-1 has a number of other identified physiological roles
(fig 2). In particular, in the kidney, ETB receptors, apart from
being present on endothelial cells where they cause vasodi-
latation, are also highly expressed in the renal tubular
epithelial cells. Here the ETB receptors appear to respond to
intra-renal ET production preventing the actions of vaso-
pressin and inhibiting Na/K-ATPase, which results in net salt
and water loss.10 This assumption is supported by the
observation that ETB gene knockout mice have salt sensitive
hypertension11; in addition, in the kidney, collecting duct
derived ET-1 has been shown to be an important physiologic
regulator of renal sodium excretion, as observed in collecting
duct ET-1 knockout mice.w9 ET-1 also plays a critical role in
Hormones Peptides Physico-chemical stimuli
Xenobiotics
Blood components
Inhibition
Adrenaline
Angiotensin II
Vasopressin
Insulin
Cortisol
Cytokines
IL-1
TGF-
Endotoxin
Endothelin
Hypoxia
Shear stress (low)
Osmolarity
Thrombin
Glucose
Oxidised LDL
Prostacyclin
Nitric oxide
ANP, BNP, CNP
Heparin
Shear stress (high)
Nucleus
Promoter ET-1 gene
PreproET-1 mRNA
Big ET-1
ET-1
ET-1
+
+
+
+
+
–
Endothelial cell
Furin-like
enzyme
Endothelin
converting
enzyme
PreproET-1
A23187
Cyclosporin
Figure 1 Factors regulating the
synthesis of endothelin-1 (ET-1). ANP,
atrial natriuretic peptide; BNP, brain
natriuretic peptide; CNP, C type
natriuretic peptide; IL-1, interleukin-1;
LDL, low density lipoprotein; TGF, tissue
growth factor.
Table 3 Classification of endothelin converting enzyme
inhibitors
Selective ECE inhibitors
Dual ECE/NEP
inhibitors
Triple ECE/NEP/ACE
inhibitors
c Natural product c NEP.ECE c Potent
FR 901532 (WS 79089B) Phosphoramidon SCH 54470
B90063 CGS 26303
WS 75624B SLV 306
c Synthetic compound c ECE.NEP c Moderate
SM 19712 CGS 34043 SA 6817
PD 069185 CGS26582
CGS 35066
ACE, angiotensin converting enzyme; ECE, endothelin converting
enzyme; NEP, neutral endopeptidase.
Table 4 Peptide and non-peptide ET receptor
antagonists*
ET receptor selectivity
ETA ETB ETA/ETB
Peptide antagonists
BQ123 IRL2500 TAK044
BQ485 RES7011 PD142893
BQ153 BQ788 PD145065
BQ610
FR139317
PD151242
Non-peptide antagonists in clinical
development
Darusentan (approx 150-fold ETA
selective v ETB)
Enrasentan
Tezosentan (iv)
Ambrisentan (approx 260-fold ETA
selective v ETB)
Atrasentan (approx 1860-fold ETA
selective v ETB)
Bosentan
Sitaxsentan (approx 6500-fold ETA
selective v ETB)
*The peptide compounds initially developed were subject to hydrolysation
and subsequent inactivation, by peptidases in the gastrointestinal and
circulatory system, and orally available, non-peptide antagonists are
currently the main focus of clinical research.
ETA selectivity is generally taken as .100-fold selectivity for the ETA
over the ETB receptors and ETB selectivity as 10–100-fold selectivity for the
ETB over the ETA receptors. Davenport AP. International Union of
Pharmacology. XXIX. Update on endothelin receptor nomenclature.
Pharmacol Rev 2002;54:219–6.
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embryonic development through both ETA and ETB recep-
tors.12
THERAPEUTIC INTERVENTION
Experimental and preclinical studies have highlighted the
powerful actions of ET-1 as a vasoconstrictor, growth
promoter, and pro-inflammatory agent, as well as a potential
therapeutic role for endothelin antagonists in different
cardiovascular and non-cardiovascular diseases. In particular,
patients with pulmonary hypertension, heart failure, as well
as arterial hypertension, renal dysfunction, and atherosclero-
sis, might benefit from treatment with endothelin antago-
nists.
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a condition
characterised by sustained elevation of pulmonary arterial
pressure, caused by progressive obliteration of the pulmonary
vascular bed, leading to increasing dyspnoea on exertion,
fatigue, and progression to right ventricular failure.w10 This
condition has a poor prognosis, despite current treatment
with oxygen therapy, diuretics, digoxin, and vasodilators.
Until recently, the only agent specifically licensed for the
treatment of severe PAH (World Health Organization func-
tional classes III and IV) was epoprostenol, which is given by
continuous intravenous infusion via an indwelling catheter:
its administration is associated with risks of serious
complications (infection or catheter correlated thrombosis,
rebound hypertension).
Endothelin antagonism in PAH
PAH is associated with endothelial dysfunction, which results
in impaired vasodilatation, exaggerated vasoconstriction, and
activation of the endothelin system.w11 The role of ET-1 in
PAH is supported by various studies,13 w12 and these findings
have led to a rational therapeutic approach provided by
endothelin receptor antagonists. In 2001 an early rando-
mised, placebo controlled trial evaluated the effects of
bosentan on exercise capacity and cardiopulmonary haemo-
dynamics in 32 PAH patients, as well as its safety and
tolerability. Bosentan improved exercise capacity as assessed
by an increase in the six minute walking distance; in
addition, nine out of the 21 bosentan treated patients
improved their WHO functional class from III to II compared
with only one of the 11 controls.14
The subsequent double blind, placebo controlled, multi-
centre BREATHE-1 (bosentan randomised trial of endothelin
receptor antagonist therapy for pulmonary hypertension)
trial confirmed these encouraging preliminary findings.15 In
this study, 213 PAH patients were enrolled and randomly
assigned to bosentan 125 or 250 mg twice daily. Bosentan
improved exercise capacity and WHO functional class, and
increased time to clinical worsening. However, although well
tolerated, it produced raised liver enzymes in 5% of patients
on 125 mg and in 14% of patients on 250 mg.
On the basis of the data derived from these two trials,
bosentan was approved for the treatment of PAH in patients
with grade III WHO functional status; in addition, a one year
follow up study suggests a sustained benefit on exercise
capacity and haemodynamics.w13 A selective ETA antagonist,
sitaxsentan, is also currently being investigated for the
treatment of PAH, after the preliminary positive results
observed in the STRIDE-1 (sitaxsentan to relieve impaired
exercise in pulmonary arterial hypertension) trial.w14
Unwanted effects
The clinical use of bosentan is associated with some safety
issues. The most serious adverse event reported is a dose
related hepatotoxicity. It occurs with elevations in amino-
transferase, in most cases without any symptoms and more
commonly when higher doses of bosentan were used. Its
administration is also contraindicated in patients receiving
glibenclamide and cyclosporine A. Other side effects include
headache, flushing, and hypotension, and are usually of mild
to moderate intensity. Decrease in haemoglobin concentra-
tion has also been reported. In addition, studies in animals
have shown reproductive toxicity, including teratogenicity
and embryotoxicity. For these reasons, the EMEA has
recommended ongoing post-marketing surveillance.
Although the safety issues impose a careful monitoring of
the therapy, the benefits shown in clinical trials, together
with the ease of administration (125 mg twice daily oral
dosing), suggest that bosentan may be a valid option for
treatment of PAH patients of WHO functional class III, before
considering intravenous infusion of epoprostenol (AJ
Peacock, personal communication, 2004).
Heart failure
Chronic heart failure (CHF) is a major cause of cardiovas-
cular mortality and morbidity. In most cases it is char-
acterised by low cardiac output, leading to progressive
haemodynamic and neurohumoral modifications, such as
peripheral vasoconstriction, salt and water retention, and
activation of the sympathetic and renin-angiotensin systems
(RAS).w15
The endothelin system is activated in patients with CHF, as
with other neurohumoral systems. Plasma big ET-1 and ET-1
concentrations have been correlated with clinical and
haemodynamic measures of severity in patients with CHF
and inversely with prognosis.16 17 w16 w17 In addition, while
ET-1 seems to exert a positive inotropic effect in the normal
heart, an increase in myocardial contractility following ETA
receptor blockade has been reported in the failing heart,
suggesting that ET-1 may have a negative inotropic effect.w18
A number of large phase III studies of selective ETA and
mixed ETA/ETB receptor antagonists have now been com-
pleted in both acute heart failure (AHF) and CHF. Although
initial experimental and acute haemodynamic studies were
favourable,18 w19 w20 the available information suggests that
no clinical benefits derive from the use of endothelin
antagonists in these conditions.
Clinical trials in acute and chronic heart failure
The RITZ project (randomised intravenous tezosentan)
consisted of a group of four double blind, randomised and
placebo controlled trials, assessing the effects of the
intravenous mixed ETA/ETB receptor antagonist tezosentan
in AHF. Apart from RITZ-2, in which tezosentan, at a dose of
50 mg/hour, significantly improved cardiac index and
reduced pulmonary capillary wedge pressure with a good
safety profile,w21 the other trials failed to demonstrate any
beneficial effect of endothelin antagonism.
With regard to CHF, the first phase III study to be reported
was the ENCOR (enrasentan clinical outcomes randomised)
trial, which used the oral mixed ETA/ETB receptor antagonist,
enrasentan. Enrasentan treatment did not improve clinical
status in these patients. In addition, it was associated with
three times the hospitalisation rate, a trend towards greater
mortality, and was not well tolerated. The subsequent
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ENABLE (I/II) (endothelin antagonist bosentan for lowering
cardiac events) and EARTH (endothelin antagonist receptor
trial in heart failure) trials have also shown disappointing
results.
Overall, interest in the possible use of endothelin antago-
nists in heart failure has now considerably declined. The
isolated positive results of RITZ-2 study may hold out some
promise for those who believe that endothelin antagonists
may still have a therapeutic role in AHF, once the right
timing of the intervention and the correct dose are identified.
Experimental evidence from animal models suggests that
early initiation of a mixed ETA/ETB receptor antagonist post-
myocardial infarction leads to adverse effect and poor
outcome.w22 These data add on to recent studies in CHF
animal models, where early use of an ETA receptor antagonist
causes further activation of the RAS and, in addition, results
in sodium retention, without offering any substantial
benefit.w23 Better results may also be obtained by selecting
those patients with a high degree of pulmonary hyperten-
sion.w20 Whether combined ECE and NEP inhibition would
provide a more effective intervention than endothelin
receptor antagonism also remains to be established.
NEW THERAPEUTIC PERSPECTIVES
Heart failure and pulmonary hypertension are not the only
therapeutic areas in which endothelin antagonism has been
investigated. Currently, there are interesting possibilities, in
terms of potential benefit, in the treatment of both arterial
hypertension and chronic renal failure (CRF); in addition,
animal studies suggest a role for therapeutic endothelin
antagonism in atherosclerosis.
Arterial hypertension
A number of studies have investigated the possible role
played by endothelin in arterial hypertension. Certain animal
models of experimental hypertension, in particular the salt
sensitive and low renin forms, are associated with enhanced
activity of ET-1.19 Data from different groups suggest
increased vascular endothelin activity in patients with
essential hypertension, as manifested by greater forearm
vasodilatation following the infusion of endothelin receptor
antagonists, compared to normotensive subjects.w24 w25 In
addition, black hypertensive patients, who are often char-
acterised by low renin values, have been shown to have
higher plasma ET-1 concentrations than white hypertensives
and to have enhanced ETA-dependent vasoconstrictor
tone.w26 w27
One of the first studies evaluating the effects of systemic
endothelin antagonism on blood pressure was published in
1998: in a cohort of 293 patients with essential hypertension,
the effects of bosentan and enalapril on blood pressure were
compared. Bosentan significantly lowered diastolic blood
pressure and its effect was similar to enalapril. In addition
there was no concomitant reflex activation of the RAS or the
Figure 2 Schematic representation of endothelin-1 (ET-1) actions. AVP, arginine vasopressin; GFR, glomerular filtration rate; RPF, renal plasma
flow.
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sympathetic nervous system.20 In another study conducted in
hypertensive patients, darusentan, an oral selective ETA
receptor antagonist, was efficacious in lowering both systolic
and diastolic blood pressure, compared to the placebo
group.w28 Recently, a new antagonist, with dual angiotensin
(AT1) and ETA receptor actions, has been shown to reduce
blood pressure in an experimental model of hypertension.w29
On the basis of these data, although endothelin antagonism
is unlikely to be considered as first line treatment, it could
still have a role in the future in the treatment of high risk
patients, such as black hypertensives or patients with
resistant hypertension, after an accurate risk/benefit assess-
ment.
Chronic renal failure
A large body of experimental evidence suggests the involve-
ment of ET-1 in the pathophysiology of chronic renal failure
(CRF), and endothelin antagonists have been shown to
improve renal function in experimental models of kidney
disease.3 w30 The results of a randomised, placebo controlled
study recently conducted in hypertensive subjects with CRF
highlighted the potential benefits on blood pressure and
renal function that can be achieved with endothelin
antagonism. This study aimed at comparing the effects of
ETA, ETB, and mixed ETA/ETB antagonism in CRF patients
and matched healthy controls. In CRF patients, the selective
ETA receptor antagonist BQ123 lowered systemic blood
pressure . 10 mm Hg compared with placebo, increased
renal blood flow, and reduced renal vascular resistance.9
Another benefit, which may derive from the use of
endothelin antagonism in renal failure, is related to the
possible involvement of ET-1 in parathyroid cell proliferation
in vivo, which may influence the development of secondary
hyperparathyroidism: data from experimental studies suggest
that bosentan is able to prevent parathyroid cell proliferation
in rats.w31 Given the need for better and more effective
strategies to prevent the consequences of secondary hyper-
parathyroidism in chronic renal failure, such as renal
osteodystrophy, endothelin antagonism may offer additional
benefits in this class of patients. Last, but not least,
teratogenicity is less likely to represent an issue in this
particular class of patients.
Atherosclerosis
ET-1 seems to be involved from an early stage in the
development of atherosclerosis. Increased plasma ET-1
concentrations have been demonstrated in patients with
cardiovascular risk factors such as hypercholesterolaemia,
hypertension, and diabetes mellitus.w32 In addition,
increased expression of ET-1 and ECE has been shown in
endothelial cells, vascular smooth muscle cells, and macro-
phages at different stages of atherosclerotic plaque evolu-
tion.w33 In these conditions, endothelial dysfunction (ED)
develops early on. ED is characterised by an imbalance
between vasoconstrictor (pro-inflammatory factors) and
vasodilator factors, resulting in cell growth, inflammation
and, ultimately, vascular remodelling. It is believed to
represent a very early common step in the progression to
overt atherosclerosis. Patients with established atherosclero-
sis have been shown to have a significant correlation between
plasma ET-1 concentrations and the number of atherosclero-
tic lesions, and both ETA and ETB receptors are highly
expressed in smooth muscle cells and foamy macrophages in
atherosclerotic plaques.w34 w35 Increase in nitric oxide
synthase (NOS) activity and improvement in NO mediated
vasodilatation, as well as reduction in atherosclerotic lesion
development, have been noted following endothelin antag-
onism in animal models of hypercholesterolaemia and
atherosclerosis.w36 w37 Available data in atherosclerotic
patients show an increased ET-1 mediated vascular tone,
together with an enhanced forearm vasodilatation evoked by
combined endothelin receptor blockade.21 It has also been
demonstrated that ET-1, acting through the ETA receptor,
participates in the maintenance of basal human coronary
vasoconstrictor tone and contributes to ED.w38 These data
support the role played by the ET system in the development
of ED and the progression to atherosclerosis, and suggest a
potential therapeutic role for endothelin antagonists in this
scenario.
OUTSTANDING ISSUES
Soon after its discovery, it became clear that ET-1 is involved
in many cardiovascular diseases and a number of clinical
trials with endothelin receptor antagonists have been under-
taken. However, almost 15 years on, their clinical use is
limited to bosentan in pulmonary arterial hypertension. Why
have results been so disappointing, in spite of the encoura-
ging experimental studies? To answer this question, and to
provide a brief summary of the key issues discussed in this
review, we need to focus on the following.
Doses used in clinical trials
Two points need to be considered: efficacy and safety.
Initially, in the hope of better results, relatively high doses
of endothelin antagonists were used, and there has been
considerable debate as to whether the doses in these studies
have been too high, leading to worse outcomes. Indeed, the
use of high doses has been associated with higher incidence
of unwanted effects, such as liver toxicity, and the propensity
for fluid retention when on bosentan. It has been suggested
that foreknowledge of this effect could have allowed optimal
clinical management (that is, more aggressive concomitant
diuretic therapy) and, therefore, safer use of the drug.
Endothelin antagonism: key points
c Endothelin-1 (ET-1) is a broadly active and extremely
potent vasoconstrictor
c ET-1 is involved in the pathophysiology of pulmonary
arterial hypertension, heart failure, systemic hypertension,
renal dysfunction, and atherosclerosis
c The discovery of several compounds acting as endothelin
antagonists has prompted research towards their use in
clinical practice
c Bosentan is a combined ETA/ETB receptor antagonist, and
the first compound of its class to be approved and
marketed for the treatment of pulmonary arterial hyper-
tension
c Bosentan use requires careful monitoring due to the dose
dependent liver toxicity and is contraindicated in preg-
nancy because of teratogenicity
c Endothelin antagonists in heart failure have shown
disappointing results, the reasons for which are still
unclear
c Endothelin antagonists also show therapeutic potential in
chronic renal failure, arterial hypertension, and athero-
sclerosis
830
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Selectivity of endothelin antagonism
Whether selective ETA or combined ETA/ETB receptor
antagonism may represent the best strategy for therapeutic
modulation of ET receptors has been a matter of major
controversy. The different actions of ET-1 on the ETA and ETB
receptors on blood vessels, and the role played by ETB
receptors in salt and water balance, endothelium dependent
vasodilatation, and in the clearance of circulating ET-1,
suggest that selective ETA antagonism might be the best
approach. However, in disease states, these two receptors
appear to be differently regulated and expressed, as
evidenced by studies conducted in left ventricular systolic
dysfunction and in atherosclerosis.w39 w40 Taken together,
these findings underline the complexity of the role played by
ET-1 in cardiovascular disease, as well as the difficulty in
knowing which receptor to target. For this reason, further
studies elucidating the exact role played by endothelin
receptors are warranted.
Disease and disease state
ET-1 antagonism is effective in PAH, which is a serious but
rare disease, whereas the overall effect in more common
cardiovascular diseases may be considered modest, in spite of
the promising results obtained in experimental studies. A
possible explanation is that haemodynamic parameters may
be a poor surrogate for clinical efficacy and do not necessarily
convert into benefits for patients, and that what we know
about one disease may not translate to another. Indeed, the
poor outcome in CHF does not mean that there may not be
benefits elsewhere.
Teratogenicity
Although most of the available data are on bosentan, this is
undoubtedly likely to be a class effect. As already mentioned,
studies in animals have shown dose dependent teratogenic
effects, including malformation of the head, mouth, face, and
large blood vessels, which occur during the first trimester of
pregnancy. This may limit the clinical impact of endothelin
receptor antagonists and, overall, impose a strict and careful
monitoring of the treatment.
CONCLUSIONS
The development of endothelin antagonists presented a novel
and potentially interesting therapeutic intervention in
patients with cardiovascular disease. This class of drugs has
proven its promise in pulmonary hypertension but failed,
until now, to demonstrate clinical utility in patients with
heart failure.
Whether combined ECE and NEP inhibitors will be more
efficacious in the treatment of heart failure remains to be
established but, undoubtedly, chronic renal failure, arterial
hypertension, and atherosclerosis represent interesting
research fields for future studies.
Additional references appear on the Heart website—http://
www.heartjnl.com/supplemental
Authors’ affiliations
. . . . . . . . . . . . . . . . . .
T Attina`, R Camidge, D J Webb, Clinical Research Centre, Department
of Medical Sciences, University of Edinburgh, Edinburgh, UK
D E Newby, Department of Cardiology, Royal Infirmary, Edinburgh, UK
Competing interest statement: Professor Webb has, in the past, provided
advice to pharmaceutical companies (Abbott, Actelion, Astra Zeneca,
BMS, Encysive, Roche) on the clinical development of endothelin
antagonists for cardiovascular disease.
REFERENCES
1 Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor
peptide produced by vascular endothelial cells. Nature 1988;332:411–5.
c This is the original landmark report of the discovery of endothelin-1,
including the isolation and sequencing of the peptide, identification of
the gene sequence for its generation, and the pathway of production.
This paper also highlights the vascular pharmacology and the pivotal
role of ET-1 in vasoconstriction and hypertension.
2 Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in
health and disease. J Hypertens 1998;16:1081–98.
3 Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353:133–8.
c A concise review on endothelin antagonists and their use in
experimental and initial clinical studies.
4 Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in
health and disease. Ann Rev Pharmacol Toxicol 2001;41:851–76.
c A comprehensive and updated review highlighting the involvement of
endothelin-1 in the pathophysiology of cardiovascular disease.
5 Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-
1 to basal vascular tone. Lancet 1994;344:852–4.
c An important early clinical study showing the involvement of
endothelin-1 in the maintenance of basal vascular tone.
6 Loeffler BD. Endothelin-converting enzyme inhibitors: current status and
perspectives. J Cardiovasc Pharmacol 2000;35(suppl 2):79–82.
7 Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-
mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis
and by endothelin-B receptor blockade. Circulation 1998;97:752–6.
8 Strachan FE, Spratt JC, Wilkinson IB, et al. Systemic blockade of the
endothelin-B receptor increases peripheral vascular resistance in healthy men.
Hypertension 1999;33:581–5.
9 Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism
reduces blood pressure and increases renal blood flow in hypertensive
patients with chronic renal failure. Circulation 2004;109:1186–93.
c An important clinical trial highlighting the potential benefit of
endothelin antagonism in renal failure patients.
10 Rabelink TJ, Kaasjager KA, Stroes ES, et al. Endothelin in renal
pathophysiology: from experimental to therapeutic application. Kidney
International 1996;50:1827–33.
11 Gariepy CE, Ohuchi T, Williams SC, et al. Salt-sensitive hypertension in
endothelin-B receptor-deficient rats. J Clin Invest 2000;105:925–33.
12 Kurihara Y, Kurihara H, Oda H, et al. Aortic arch malformations and
ventricular septal defect in mice deficient in endothelin 1. J Clin Invest
1995;96:293–300.
13 Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the
lungs of patients with pulmonary hypertension. N Engl J Med
1993;326:1732–9.
14 Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-
receptor antagonist bosentan in patients with pulmonary hypertension: a
randomized placebo-controlled study. Lancet 2001;358:1119–23.
15 Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial
hypertension. N Engl J Med 2002;346:896–903.
c An important clinical trial evaluating efficacy and safety of bosentan in
pulmonary hypertension.
16 Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated
vasoconstriction in severe chronic heart failure. Lancet 1995;346:732–6.
17 Pacher R, Stanek B, et al. Prognostic impact of big endothelin-1 plasma
concentrations compared with invasive hemodynamic evaluation in severe
heart failure. J Am Coll Cardiol 1996;27:633–41.
18 Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin
pathway improves long-term survival in heart failure. Nature
1996;384:353–5.
19 Taddei S, Virdis A, Ghiadoni L, et al. Vasoconstriction to endogenous
endothelin-1 is increased in the peripheral circulation of patients with essential
hypertension. Circulation 1999;100:1680–3.
20 Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin receptor
antagonist, bosentan, on blood pressure in patients with essential
hypertension. Bosentan hypertension investigators. N Engl J Med
1998;338:784–90.
c A large clinical trial investigating the effects of bosentan suggesting
that ET-1 antagonism may be as effective in lowering blood pressure as
ACE inhibition.
21 Bohm F, Ahlborg G, Johsansson BL, et al. Combined endothelin receptor
blockade evokes enhanced vasodilatation in patients with atherosclerosis.
Arterioscler Thromb Vasc Biol 2002;22:674–9.
Additional references appear on the Heart
website—http://www.heartjnl.com/supplemental
831
EDUCATION IN HEART
www.heartjnl.com
